reports
BLINK CHARGING ANNOUNCES FIRST QUARTER REVENUE GROWTH OF 73% TO $37.6 ...
BLINK CHARGING ANNOUNCES FIRST QUARTER REVENUE GROWTH OF 73% TO $37.6 MILLION AND GROSS MARGIN OF 36% ●First quarter 2024 total revenues increased 73% to $37.6 million compared to $21.7 million in first quarter of 2023 ●68% increase in product revenues to $27.5 million in first quarter of 2024 compared to $16.4 million in first quarter of 2023 ●72% increase in service revenues to $8.2 million in first quarter of 2024 compared to $4.8 million in first quarter 2023 ●195% increase in gross profit to $13.4 million in first quarter of 2024 compared to $4.5 million in first quarter of 2023 ●36% ...
Oncternal Therapeutics Provides Business Update and Announces First Qu...
Oncternal Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results Fourth dosing cohort at 300 mg per day is fully enrolled for the Phase 1/2 study with ONCT-534, our dual-action androgen receptor inhibitor (DAARI), for patients with advanced prostate cancer who are resistant to approved androgen receptor pathway inhibitors; initial data readout expected in the latter part of the second quarterPhase 1/2 study for ONCT-808, our ROR1-targeting autologous CAR T cell therapy, for patients with relapsed or refractory aggressive B-cell lymphoma, including patients ...
Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results a...
Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update Over 17,500 total prescriptions for VOQUEZNA® products have been dispensed, launch-to-date, a 361% increase since last quarterly report Net revenues of $1.9 million reported for the first full quarter of launch Cigna Healthcare recently added VOQUEZNA tablets to its formularies, broadening coverage to approximately 48% of all U.S. commercial lives National direct-to-consumer campaign, “VOQUEZNA Can Kick Some Acid,” underway across broadcast and streaming TV Management to host conference cal...
- Wedbush Research
TXRH TEXAS ROADHOUSE INC.
RNG RINGCENTRAL INC. CLASS A
PANW PALO ALTO NETWORKS INC.
NRZ NEW RESIDENTIAL INVESTMENT CORP.
IMAX IMAX CORPORATION
GLPI GAMING AND LEISURE PROPERTIES INC.
DIN DINE BRANDS GLOBAL INC.
CXW CORECIVIC INC.
CTMX CYTOMX THERAPEUTICS INC.
CAKE CHEESECAKE FACTORY INCORPORATED
AMC AMC ENTERTAINMENT HOLDINGS INC. CLASS A
BJRI BJ'S RESTAURANTS INC.
DRI DARDEN RESTAURANTS INC.
OKTA OKTA INC. CLASS A
RCUS ARCUS BIOSCIENCES
ZS ZSCALER INC.
UBER UBER TECHNOLOGIES INC.
CRWD CROWDSTRIKE HOLDINGS INC. CLASS A
IGMS IGM BIOSCIENCES
DDOG DATADOG INC CLASS A
RVMD REVOLUTION MEDICINES
ABNB AIRBNB INC. CLASS A
PHVS PHARVARIS NV
RMBL RUMBLEON INC
APP APPLOVIN CORP
BIRD ALLBIRDS INC
JANX JANUX THERAPEUTICS INC
DDI DOUBLEDOWN INTERACTIVE CO LTD
CART MAPLEBEAR INC.
- Matthew McCartney
- Nathan Friedman
- Seth Basham
Merus Announces Financial Results for the First Quarter 2024 and Provi...
Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update Petosemtamab in combination with pembrolizumab in 1L HNSCC initial interim clinical data at 2024 ASCO Annual Meeting; preparing for a potential phase 3 trialZeno BLA accepted for priority review by the FDA for the treatment of NRG1+ NSCLC and PDACBased on the Company’s current operating plan, existing cash, cash equivalents and marketable securities expected to fund Merus’ operations into 2027 UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: MRUS) (Merus, the...
Erasca Reports First Quarter 2024 Business Updates and Financial Resul...
Erasca Reports First Quarter 2024 Business Updates and Financial Results Median OS of 13-14 months for naporafenib plus trametinib in pooled analysis of patients with NRASm melanoma Strengthened balance sheet with private placement financing from high-quality new and existing healthcare-focused investors Pro forma cash, cash equivalents, and marketable securities of $334 million is expected to fund operations into H2 2026 SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, an...
Inozyme Pharma to Participate at the Bank of America Securities 2024 H...
Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Doug Treco, Ph.D., CEO and Chairman of Inozyme, will participate in a fireside chat at the Bank of America Securities 2024 Health Care Conference on Wednesday, May 15, 2024 from 6:40-7:10pm ET / 3:40-4:10pm PT. A live webcast of the firesi...
Blink Charging Launches New Preventative Maintenance Program, Blink Ca...
Blink Charging Launches New Preventative Maintenance Program, Blink Care is an optional maintenance program designed to reduce charger downtime and provide a more seamless charging experience. Bowie, Md., May 08, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: BLNK) (“Blink” or the “Company”), a leading global manufacturer, owner, operator and provider of electric vehicle (EV) charging equipment and services, today announced the launch of , a new, optional preventative maintenance program aimed at maximizing customer satisfaction and ensuring charger reliability at Blink charging locations. is des...
Merus gibt Annahme und vorrangige Prüfung des Lizenzantrags für das Bi...
Merus gibt Annahme und vorrangige Prüfung des Lizenzantrags für das Biologikum Zeno zur Behandlung von NRG1+ NSCLC und PDAC durch die US-Zulassungsbehörde FDA bekannt Nach der Zulassung wird Zeno die erste zielgerichtete Therapie für NRG1+ Krebs sein UTRECHT, Niederlande und CAMBRIDGE, Massachusetts, May 07, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: MRUS) (Merus, das Unternehmen, wir oder unser), ein Unternehmen aus dem Bereich der klinischen Onkologie, das innovative multispezifische Antikörper in voller Länge (Biclonics® und Triclonics®) entwickelt, hat heute bekanntgegeben, dass die US-Zula...
Merus annonce l’acceptation par la FDA américaine et l’examen priorita...
Merus annonce l’acceptation par la FDA américaine et l’examen prioritaire de la demande de licence de produit biologique relative à Zeno dans le traitement du CPNPC et de l’ACP NRG1+ S’il est approuvé, Zeno sera le premier traitement ciblé pour le cancer NRG1+ UTRECHT, Pays-Bas et CAMBRIDGE, Massachusetts, 07 mai 2024 (GLOBE NEWSWIRE) -- (Nasdaq : Merus (Merus, la Société, nous ou notre/nos), une société d’oncologie au stade clinique développant des anticorps multispécifiques de pleine longueur innovants (Biclonics® et Triclonics®), a annoncé, ce jour, que la Food and Drug Administrat...
PubMatic Announces Record First Quarter 2024 Financial Results
PubMatic Announces Record First Quarter 2024 Financial Results Revenue and adjusted EBITDA exceeded guidance; Delivered accelerated year-over-year revenue growth of 20%; Net loss of $(2.5) million or (4)% margin; Adjusted EBITDA of $15.1 million or 23% margin, more than double from Q1 2023; Supply Path Optimization represented 50% of total activity; Generated $24.3 million in cash from operating activities and tripled free cash flow over Q1 2023 to $16.3 million NO-HEADQUARTERS/REDWOOD CITY, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- PubMatic, Inc. (Nasdaq: PUBM), an independent techn...
AV’s Switchblade 600 Selected for Tranche 1 of the U.S. Department of ...
ARLINGTON, Va.--(BUSINESS WIRE)-- AeroVironment’s (AV) Switchblade 600 loitering munition system has been selected for Tranche 1 of the first iteration of the U.S. Department of Defense’s (DoD) Replicator initiative. AV’s Switchblade 600 is a man-portable, extended-range loitering munition system equipped with an anti-armor warhead for engaging larger, hardened targets at greater distances. The first iteration of the Replicator initiative aims to accelerate all-domain, attritable autonomous systems to warfighters at speed and scale. This press release features multimedia. View the full releas...
Inozyme Pharma Reports First Quarter 2024 Financial Results and Provid...
Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights - Interim data from SEAPORT-1, a Phase 1 trial of INZ-701 in patients with end-stage kidney disease receiving hemodialysis, on track for fourth quarter of 2024 - - Interim data from ENERGY-1, a Phase 1b trial of INZ-701 in infants with ENPP1 Deficiency, on track for second half of 2024 - - Cash, cash equivalents, and short-term investments as of March 31, 2024, expected to fund operations into the fourth quarter of 2025 - BOSTON, May 07, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: INZY) (“the Company”...
Erasca to Present at the Bank of America Health Care Conference
Erasca to Present at the Bank of America Health Care Conference SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Bank of America Health Care Conference being held at the Encore Hotel in Las Vegas, Nevada. Management will present on Wednesday, May 15, 2024 at 4:20 pm Pacific Time and will also participate in one-on-one investor meetings. A live audio webca...
- David Carlson
- David Nierengarten
- Dennis Pak
- Martin Fan
Merus Announces U.S. FDA Acceptance and Priority Review of Biologics L...
Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDAC If approved, Zeno will be the first targeted therapy for NRG1+ cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review a Biologics License Application...
- Jonathan Moreland
RF REGIONS FINANCIAL CORPORATION
NEOG NEOGEN CORPORATION
LGND LIGAND PHARMACEUTICALS INCORPORATED
INTC INTEL CORPORATION
HXL HEXCEL CORPORATION
FFIN FIRST FINANCIAL BANKSHARES INC
EGBN EAGLE BANCORP INC.
DLTR DOLLAR TREE INC.
CINF CINCINNATI FINANCIAL CORPORATION
CHDN CHURCHILL DOWNS INCORPORATED
SWKS SKYWORKS SOLUTIONS INC.
HTLD HEARTLAND EXPRESS INC.
ZUMZ ZUMIEZ INC.
TRT TRIO TECH INTERNATIONAL
CET CENTRAL SECURITIES CORP.
LIND LINDBLAD EXPEDITIONS HOLDINGS
WDFC WD-40 COMPANY
FEIM FREQUENCY ELECTRONICS INC.
AINC ASHFORD
CLF CLIFFS NATURAL RESOURCES INC.
PWOD PENNS WOODS BANCORP INC.
ATOM ATOMERA
LOVE LOVESAC
FVCB FVCBANKCORP
INMB INMUNE BIO
MCFT INC.
CAPR MASTERCRAFT BOAT HOLDINGS
RYES CAPRICOR THERAPEUTICS
HQL PATRIOT MINEFINDERS INC.
SOWG TEKLA LIFE SCIENCES INVESTORS
CPZ SOW GOOD INC.
AUID CALAMOS LONG/SHORT EQUITY AND DYNAMIC INCOME TRUST
JBHT IPSIDY INC.
TBBK J.B. HUNT TRANSPORT SERVICES
MPA INC.
FTHY THE BANCORP
AIKI INC.
BHVN BLACKROCK MUNIYIELD PENNSYLVANIA FD
BUKS FIRST TRUST HIGH YIELD OPPORTUNITIES 2027 TERM FUND
ACRV AIKIDO PHARMA INC.
ZURA BIOHAVEN LTD
ABEO BUTLER NATIONAL CORP
STCN ACRIVON THERAPEUTICS INC
KRRO ZURA BIO LTD
LSXMA ABEONA THERAPEUTICS INC.
EP STEEL CONNECT INC
INTZ KORRO BIO INC
LGVN LIBERTY SIRIUSXM GROUP
OCX EMPIRE PETROLEUM CORP
EYPT INTRUSION INC
IZEA LONGEVERON INC
CFFI ONCOCYTE CORPORATION
EYEPOINT PHARMACEUTICALS
INC.
IZEA WORLDWIDE INC
C&F FINANCIAL CORPORATION
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 563...
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: INZY) (“Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that it granted stock options to one new employee to purchase shares of the Company’s common stock, pursuant to the Company’s 2023 Inducement Stock Incentive Plan, as an inducement material to the new employee entering into employment with the Company in acc...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.